The anti-CD133-IgY-abrine showed to reduce cell viability of C6 CSC in vitro and decreased tumor volume after implantation of malignant glioma stem cells in vivo, representing a low-cost tool for the treatment of GBM [86]. Here, PROM1 is linked to glioblastoma.